NDC 70771-1708-01 - BORTEZOMIB
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 70771-1708
- Requested NDC
- 70771-1708-01
- Package NDCs from labels
- 70771-1708-1, 70771-1708-01
- Manufacturer
- Zydus Lifesciences Limited | Zydus Hospira Oncology Private Limited
- Effective date
- 2022-05-05
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| BORTEZOMIB - Zydus Lifesciences Limited | Zydus Hospira Oncology Private Limited | Zydus Lifesciences Limited | Zydus Hospira Oncology Private Limited | 2022-05-05 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 70771-1708-1 | BORTEZOMIB | 3.5 mL in 1 VIAL, SINGLE-DOSE | INJECTION, POWDER, LYOPHILIZED, | 3.5 | 1 | |
| 70771-1708-1 | BORTEZOMIB | 1 in 1 CARTON | INJECTION, POWDER, LYOPHILIZED, | 1 | 1 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 70771-1708 | BORTEZOMIB INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [ZYDUS LIFESCIENCES LIMITED] | 1 | Current NDC, Legacy NDC, 2 package rows | 20220505_582c7c0d-fa25-4586-8157-a1e2653d72d9.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| BORTEZOMIB | BORTEZOMIB | Sagent Pharmaceuticals | 945fbaf0-7a79-4676-aa90-e9a213c0654f | 2025-05-05 | Warnings, Adverse reactions | 402243 69G8BD63PP |
| Bortezomib | BORTEZOMIB | Fresenius Kabi USA, LLC | 3494c357-a692-4e55-89e1-93532b0baef7 | 2025-03-27 | Warnings, Adverse reactions | 402243 69G8BD63PP |
| BORTEZOMIB | BORTEZOMIB | Zydus Pharmaceuticals USA Inc. | 0eb8daef-18da-43bb-b7c6-38c4c8b5dd80 | 2024-12-05 | Warnings, Adverse reactions | ANDA210204 402243 69G8BD63PP |
| Bortezomib | BORTEZOMIB | Shilpa Medicare Limited | 61539d49-dc21-4576-8813-4bc8abf3868c | 2024-08-30 | Warnings, Adverse reactions | 69G8BD63PP |
| Bortezomib | BORTEZOMIB | Camber Pharmaceuticals, Inc. | 04aafa6a-a50d-4a47-a831-be8e8bb992ac | 2024-07-22 | Warnings, Adverse reactions | 402243 69G8BD63PP |
| Bortezomib | BORTEZOMIB | Dr.Reddy's Laboratories, Inc. | 664bee24-7af2-2099-ac99-5dd71a1e5a14 | 2024-05-17 | Warnings, Adverse reactions | 402243 69G8BD63PP |
| Bortezomib | BORTEZOMIB | Hospira, Inc. | 41e3de39-8278-4a75-badf-601e4602080d | 2024-04-09 | Warnings, Adverse reactions | 402243 69G8BD63PP |
| MANNITOL | MANNITOL | HF Acquisition Co LLC, DBA HealthFirst | 999ce711-2d5b-0d7d-e053-2995a90a2689 | 2024-01-27 | Warnings, Adverse reactions | 3OWL53L36A |
| BORTEZOMIB | BORTEZOMIB | Eugia US LLC | 76c7c3a5-fd2f-403f-85fd-65a64538eee7 | 2023-10-20 | Warnings, Adverse reactions | 402243 69G8BD63PP |
| Bortezomib | BORTEZOMIB | Sintetica US LLC | d79a71ec-b46d-4961-ad05-8980915cba94 | 2023-10-09 | Warnings, Adverse reactions | 402243 69G8BD63PP |
| Mannitol | MANNITOL | B. Braun Medical Inc. | d12cc802-b538-4065-a264-f474ff3b3043 | 2023-08-15 | Warnings, Adverse reactions | 3OWL53L36A |
| Mannitol | MANNITOL | Fresenius Kabi USA, LLC | c395e13d-6ea1-4104-8b37-669cfb982f04 | 2023-03-16 | Warnings, Adverse reactions | 3OWL53L36A |
| BORTEZOMIB | BORTEZOMIB | Hospira, Inc. | 9fdf6169-699f-40eb-bda1-760253062b3c | 2023-02-27 | Warnings, Adverse reactions | 69G8BD63PP |
| Bortezomib | BORTEZOMIB | Novadoz Pharmaceuticals LLC | d41340c2-7fe8-42b2-aaa5-c9f9b0e9b50e | 2022-07-20 | Warnings, Adverse reactions | 402243 69G8BD63PP |
| Bortezomib | BORTEZOMIB | BluePoint Laboratories | 12500f21-8e2f-4bcd-861e-4dfca843da2e | 2022-05-16 | Warnings, Adverse reactions | 402243 69G8BD63PP |
| Bortezomib | BORTEZOMIB | Qilu Pharmaceutical Co., Ltd. | aef02171-bf8a-43ad-b40c-7642623f9802 | 2022-05-09 | Warnings, Adverse reactions | 402243 69G8BD63PP |
| BORTEZOMIB | BORTEZOMIB | Zydus Lifesciences Limited | 582c7c0d-fa25-4586-8157-a1e2653d72d9 | 2022-05-05 | ANDA210204 70771-1708-1 70771-1708 70771170801 402243 a7ff2205-566b-4fb5-8f33-bf73377ee093 582c7c0d-fa25-4586-8157-a1e2653d72d9 69G8BD63PP | |
| Bortezomib | BORTEZOMIB | Pharmascience Inc. | 191d231a-1fbd-4a65-9d33-d5dc03bac381 | 2022-05-02 | Warnings, Adverse reactions | 402243 69G8BD63PP |
| Bortezomib | BORTEZOMIB | Waverley Pharma Inc | a73d7ea7-d068-4d25-b368-fc3db1898be2 | 2022-04-13 | Warnings, Adverse reactions | 402243 69G8BD63PP |
| bortezomib | BORTEZOMIB | Hikma Pharmaceuticals USA Inc. | 854be921-5fd9-482a-8432-a0c0241625f8 | 2021-11-22 | Warnings, Adverse reactions | 402243 69G8BD63PP |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.